ArticlePhysics and imaging in radiation oncology2026
Impact of respiratory motion on dose to the airways in central and ultra-central lung stereotactic ablative body radiotherapy.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Stereotactic ablative body radiotherapy (SABR) achieves excellent local control in medically inoperable non-small cell lung cancer. However, treating central and ultra-central tumours carries significant risks to adjacent critical structures, notably the central airways. This study evaluated the suitability of average value intensity projection (AvIP) imaging for airway delineation and assessed the adequacy of a 5 mm planning risk volume (PRV), by quantifying the influence of respiratory motion on dose to the airways using four-dimensional (4D) dose accumulation. Materials and methods: Eighteen patients (11 ultra-central, 7 central) treated with 60 Gy in 8 fractions were retrospectively analysed. Clinical 4D computed tomography (CT) datasets were used to capture 10 respiratory phases. Central airway contours (trachea, main bronchi, bronchial tree) were delineated on the AvIP and deformably propagated across all phases. Dose was recalculated per phase and accumulated back into a single distribution using the deformable registration for comparison with the AvIP-based plan. Results: Maximum differences of 5 Gy were observed for the airway Conclusions: Dose to the airways can be significantly underestimated when motion is not incorporated into treatment planning. A uniform 5 mm PRV may be inadequate in some central/ultra-central SABR cases. Patient-specific internal risk volumes merit investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.